Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
Clin Transl Oncol
.
2020 Apr;22(4):621.
doi: 10.1007/s12094-019-02198-5.
Authors
A Passaro
1
,
P Mancuso
2
,
S Gandini
3
,
G Spitaleri
4
,
V Labanca
2
,
E Guerini-Rocco
5
6
,
M Barberis
5
,
C Catania
4
,
E Del Signore
4
,
F de Marinis
4
,
F Bertolini
2
Affiliations
1
Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141, Milan, Italy. antonio.passaro@ieo.it.
2
Laboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
3
Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
4
Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141, Milan, Italy.
5
Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy.
6
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
PMID:
31432394
DOI:
10.1007/s12094-019-02198-5
Abstract
Acknowledgements section was missing.
Publication types
Published Erratum